Drug Profile
Lutetium-177 DOTA girentuximab - Telix Pharmaceuticals
Alternative Names: 177Lu-DOTA-girentuximab - Telix Pharmaceuticals; 177Lu-DOTA-girentuximab; 177Lu-Girentuximab; Lu-177-DOTA-cG250; Lu-177-DOTA-girentuximab; TLX-250Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Telix Pharmaceuticals; WILEX AG
- Developer Heidelberg Pharma AG; M. D. Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; Merck KGaA; Radboud University; Telix Pharmaceuticals
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Renal cell carcinoma
- Phase I Solid tumours
Most Recent Events
- 12 Jan 2024 Telix Pharmaceuticals suspends a phase Ib/II trial for Renal cell carcinoma (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease, Treatment-naive) in USA (IV), due to PI request(NCT05663710)
- 30 Jun 2023 Phase-II clinical trials in Renal cell carcinoma (Combination therapy, Late-stage disease, First-line therapy, Metastatic disease) in USA (IV) (NCT05663710)
- 22 Jun 2023 Pharmacodynamics data from a preclinical trial in prostate and renal cell cancer released by Telix Pharmaceuticals